In contrast, in another study, it was shown that ruxolitinib targeted and inhibited the STAT3 upstream kinase Janus kinase 1/2, which could inhibit the progression of carbon tetrachloride (CCl4)–induced liver fibrosis in mice (19, 20). This evidence concerns the gene STAT3 and Hepatic fibrosis.